Surface Oncology

Biotech · Acquired

Monoclonal antibodies and biologics targeting IL-27 and immuno-oncology pathways for cancer treatment

surfaceoncology.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
14 granted · 26 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3033PHENVOGEN, LLC——
3034Childrens Specialty Group PLLC——
3035Twenty First Century Therapeutics, Inc.——
3036Surface Oncology——
3037OPSIN BIOTHERAPEUTICS INC.——
3038TRANSIRA THERAPEUTICS LLC——
3039ECMedical LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 14 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.